These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20652729)

  • 21. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
    Jonkers IJAM; van Buren M
    Clin Exp Nephrol; 2009 Aug; 13(4):397-401. PubMed ID: 19381758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vascular and renal effects of anti-angiogenic therapy].
    Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
    Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of bevacizumab-induced hypertension by amlodipine.
    Mir O; Coriat R; Ropert S; Cabanes L; Blanchet B; Camps S; Billemont B; Knebelmann B; Goldwasser F
    Invest New Drugs; 2012 Apr; 30(2):702-7. PubMed ID: 20878444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.
    Fettner SH; Pai S; Zhu GR; Kosoglou T; Banfield CR; Batra V
    Eur J Clin Pharmacol; 1995; 48(5):351-9. PubMed ID: 8641322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension.
    Shukla M; Ibrahim MMA; Jain M; Jaiswal S; Sharma A; Hanif K; Lal J
    Eur J Pharm Sci; 2017 Nov; 109():253-261. PubMed ID: 28821435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
    Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
    J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
    Robinson ES; Matulonis UA; Ivy P; Berlin ST; Tyburski K; Penson RT; Humphreys BD
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):477-83. PubMed ID: 20056761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
    Tesařová P; Tesař V
    Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)].
    Matsui J; Funahashi Y
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):162-6. PubMed ID: 24107519
    [No Abstract]   [Full Text] [Related]  

  • 35. Proteinuria and hypertension with tyrosine kinase inhibitors.
    Kandula P; Agarwal R
    Kidney Int; 2011 Dec; 80(12):1271-7. PubMed ID: 21900879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
    Jin K; Shen Y; He K; Xu Z; Li G; Teng L
    Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
    Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
    García de Vinuesa S; Luño J; Gómez-Campderá F; Ridao N; Sánchez M; Dall'Anese C; Valderrábano F
    Nephrol Dial Transplant; 2001; 16 Suppl 1():78-81. PubMed ID: 11369828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.